+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure)



Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure)



American Journal of Cardiology 90(1): 24-28



Although the value of heart rate variability (HRV) for risk stratification after acute myocardial infarction has been demonstrated, the value of low HRV as a predictor of sudden cardiac death in patients with ischemic cardiomyopathy has not been shown convincingly to date. We retrospectively analyzed electrocardiographic data from 179 patients in the Veterans Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure to determine if HRV (expressed as the SD of the normal-to-normal RR intervals [SDNN]) would be useful as a predictor of overall mortality and sudden death. Because our goal was to identify high-risk patients, we compared patients in the lowest quartile of HRV with the remaining patients. Among the 127 patients meeting inclusion criteria, SDNN <65.3 ms (the lowest quartile) was the sole independent factor predictive of survival in a multivariate model (p = 0.0001). A Cox proportional-hazards model revealed that each increase of 10 ms in SDNN conferred a 20% decrease in risk of mortality (p = 0.0001). Furthermore, patients with SDNN <65.3 ms had a significantly increased risk of sudden death (p = 0.016). Thus, HRV was the sole independent predictor of overall mortality and was significantly associated with sudden death in this population.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011207238

Download citation: RISBibTeXText

PMID: 12088774

DOI: 10.1016/s0002-9149(02)02380-9


Related references

Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 98(23): 2574-2579, 1998

Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation : Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (Chf-Stat). Circulation 98(23): 2574-2579, 1998

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. New England Journal of Medicine 333(2): 77-82, 1995

Class III drugs and congestive heart failure: Focus on the congestive heart failure-survival trial of antiarrhythmic therapy. American Journal of Cardiology 84(9A): 103R-108R, 1999

Effects of amiodarone on the circadian pattern of sudden cardiac death (Department of Veterans Affairs Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy). American Journal of Cardiology 80(1): 45-48, 1997

Veterans Affairs Congestive Heart Failure Antiarrhythmic Trial. American Journal of Cardiology 72(16): 99F-102F, 1993

Higher dose ACE inhibitor therapy has a favorable influence on heart rate variability and circadian systolic blood pressure variability in congestive heart failure A substudy of the assessment of lisinopril in heart failure trial. Circulation 98(17 Suppl. ): I83, 1998

Prognostic value of heart rate variability in chronic congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. American Journal of Cardiology 79(7): 978-980, 1997

Frontiers in congestive heart failure: Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Congestive Heart Failure 5(4): 184-185, 1999

Congestive heart failure and continuous positive airway pressure therapy: support of a new modality for improving the prognosis and survival of patients with advanced congestive heart failure. Heart Disease 4(2): 102-109, 2002

Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. European Heart Journal 15(3): 303-310, 1994

Congestive heart failure: Survival trial of antiarrhythmic therapy (CHF STAT). Controlled Clinical Trials 13(5): 339-350, 1992

Results of the congestive heart failure survival trial of antiarrhythmic therapy. Circulation 90(4 Part 2): I546, 1994

Prognostic value of iodine-123-metaiodobenzylguanidine myocardial uptake and heart rate variability in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology 96(3): 427-431, 2005

Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure Veterans affairs cooperative studies V-HeFT I and II. Circulation 87(6 Suppl. 6): VI65-VI70, 1993